Jun 23 2016
Integrated Device Technology, Inc. (IDT) announced today that an implantable long-term glucose sensor using IDT's sensing technology has received government approval to be marketed in European Union (EU) member countries.
Maryland-based Senseonics received the CE Mark approval for its Eversense® Continuous Glucose Monitoring (CGM) System, featuring an implanted glucose sensor that lasts up to 90 days, or about six times longer than non-implantable systems currently on the market.
The IDT® sensing solution incorporates an LED driver, temperature sensor, photodiodes and other components in a compact package to drive glucose measurements, which are wirelessly communicated to an on-body wearable transmitter.
"Anyone treating diabetes knows all too well the importance of keeping close watch of glucose levels," said Dr. Andrew Dehennis, director of engineering at Senseonics. "IDT provides a unique semiconductor-based technology with extremely low power consumption, enabling the Eversense system to help the millions of people with diabetes looking for a long-lasting, accurate, easy-to-use continuous glucose monitoring system."
In developing the semiconductor for Senseonics, IDT engineers selected a technology usually used for hearing aids that can be operated at a voltage as low as 0.85 V.
"Senseonics' use of our novel technology to develop its Eversense CGM system is a great example of how miniaturized advanced electronics are contributing to improvements in medical care," said Uwe Guenther, director of mobile sensing at IDT. "The IDT technology used provides an unparalleled level of system integration to deliver the requisite quality and reliability—all in one implantable single-chip solution."
The biotech company Roche announced last month that it will market the Eversense CGM System in Italy, Germany and the Netherlands.
Source: http://www.senseonics.com/